Module 8: Lp(a) & ApoB
Lipoprotein(a) and Apolipoprotein B assessment and management.
Patient Context
Provide risk context for goal-directed interpretation
Lipoprotein(a) Assessment
Lp(a) is a genetically determined, independent risk factor for ASCVD
Thresholds: \u2265125 nmol/L elevated, \u2265175 nmol/L significantly elevated
Apolipoprotein B Assessment
ApoB reflects atherogenic particle number and is a secondary treatment target
Should You Measure Lp(a) and ApoB?
Guideline indications for when to obtain these measurements
Lp(a) Measurement
COR IIa, LOE B-NR
- Lp(a) has not been measured. Measure Lp(a) at least once for ASCVD risk assessment (COR 1, LOE B-NR).
ApoB Measurement
COR IIa, LOE B-NR
No specific indication identified based on the current patient context. ApoB is most useful when triglycerides are 150-499 mg/dL, or in patients with diabetes or metabolic syndrome.
This tool is intended for use by healthcare professionals and does not replace clinical judgment. Always refer to the full 2026 ACC/AHA Guideline on the Management of Dyslipidemia for complete recommendations.